Getting started on eversense cgm just got easier Existing Customers COVID-19 Update
Eversense USA   Eversense OUS
Getting started on eversense cgm just got easier Existing Customers COVID-19 Update
Home
Home

Patient Website
Provider Website

Eversense USA   Eversense OUS

EVIDENCE

Paragraphs
 

REAL-WORLD WEAR TIME IS THE KEY TO BETTER FINANCIAL OUTCOMES

Continuous glucose monitoring (CGM) is the gold standard of glycemic management¹, but low adherence rates have proven to limit its efficacy. Traditional CGM is associated with suboptimal adherence, which can lead to increased patient risk and unrecoverable costs for payers.

 
Selector Id
real-world-adherence-outcomes
Selector Class
impact-control impact_control_with_d

Almost 25% of traditional CGM spend is wasted²

25-percent-pie
graph

About 27% of traditional CGM users discontinue use within 1 year.³

graph

63% of traditional CGM users wear their CGM more than the clinical threshold of 70% of the time.4,5,6,7

graph

Wear time of <70% is associated with small to no measurable A1C reduction across major randomized clinical trials.8,9

Cost of traditional CGM Nonadherence

people-nonadherent

1,000

MEMBERS START ON
TRADITIONAL CGM

 

376

CGM MEMBERS ARE
NONADHERENT

37-percent

37.6%

Traditional CGM Member

wear time nonadherence¹⁰,¹¹,¹²,¹³

37-percent

37.1%

Traditional CGM Members

wearing their sensor  70% of the time¹³,¹⁴,¹⁵,¹⁶,¹⁷

OPTIMAL CGM ADHERENCE LEADS TO BETTER OUTCOMES

80-percent-pie

adherence is associated with twice the A1C reduction when compared with wear time of 41-60%.18

90-percent-pie

adherence reduces health care resource utilization, compared to traditional CGM wear time.19

  • $308 PMPY less in emergency services
  • $510 PMPY less in outpatient services

Eversense Reduces Patient Burden And Improves Adherence

 
Selector Id
section-evidence-improves
Selector Class
section-evidence-improves
sensor-circle

A 90-day fully implantable sensor that simplifies daily use by eliminating self-insertions

Water-resistant* transmitter can be removed without disturbing the sensor

transmitter-blue

Gentle silicone adhesive reduces skin irritation risk18,19

Selector Id
optimistic
Selector Class
optimistic

Find out more on how Eversense uniquely balances performance, patient insights and a lifestyle-friendly user experience

Download Publication
See Additional Product details
Selector Class
product-sheet x-overflow
 

NEXT:IMPORTANCE OF TIME IN RANGE

 
Selector Class
section-next

*1 meter for up to 30 minutes

  1. Endocrine Society Clinical Practice Guideline. Published September 2016.
  2. Yu, S., Diabetes Technology & Therapeutics, 20(6), 420-427.
  3. T1D Exchange; Why Do Some People with T1D Stop Using a Pump and CGM? 2016
  4. De Bock M. Journal of Diabetes Science and Technology. 2016;10(3):627-632.
  5. McQueen RB. Endocr Pract 2014;20:1007–1015.
  6. Picard S.Diabetes Technol Ther 2016; 18:127–135.
  7. Charleer S. The J of Clin Endo & Metab, Volume 103, Issue 3, 1 March 2018,1224–1232.
  8. Lind M. The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379-387.
  9. Battelino T. Diabetologia 2012; 55: 3155– 3162.
  10. Little SA. Diabetes Care 37.8 (2014): 2114-2112. Web. 19 Feb. 2018.
  11. Bergenstal RM. Diabetes Care 2011;34:2403-2405.
  12. Cohen O. J Diabetes Sci Technol. 2009;3(4):804-11. Published 2009 Jul.
  13. De Bock M. Journal of Diabetes Science and Technology. 2016;10(3):627-632.
  14. McQueen RB. Endocr Pract 2014;20:1007-1015.
  15. Raccah D. Diabetes Care 2009:32:2245-2250.
  16. Picard S. Diabetes Technol Ther 2016;18:127-135.
  17. Charleer S. The J of Clin Endo & Metab, Volume 103, Issue 3, 1 March 2018, 1224-1232.
  18. Bergenstal RM. N Engl J Med 2010;363:311–320pmid:20587585
  19. Data on file. Senseonics 2019.
Selector Class
section-lists
Sub Description

The advanced sensor technology and under-the-skin placement help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.

x